(21) 对研究过程可能用到的清淋药物或对症处理 CRS 的药物过敏或不耐受的患者,包括但不限于氟达拉滨和环磷酰胺或托珠单抗;已知对 anti-HER2-CAR-T 的成分过敏;或有任何严重的过敏史,例如,过敏性休克; (22) 给药前1个月内参加过其他干预性临床试验者; (23) 已经妊娠、试验期间准备妊娠或正在哺乳期的女性;...
[11]Skidmore L,Sakamuri S,Knudsen NA,et al.ARX788,a Site-specific Anti-HER2 Antibody-Drug Conjugate,Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers.Mol Cancer Ther.2020 Sep;19(9):18...
The improved functionality of CAR-CCR8-DNR T cells compared to CAR T cells against the HER2 antigen could be demonstrated in vitro and in vivo in human HER2+ tumor models.Conclusions Equipping CAR T cells with CCR8 and DNR emerges as a strategy not only limited to certain antigens, but ...
[6]Elgersma RC, Coumans RG, Huijbregts T, et al. Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985. Mol Pharm. 2015 Jun 1;12(6):1813-35. [7]Xinling ...
目前的限制:CAR-T(嵌合抗原受体T细胞)细胞治疗作为一种令人充满希望的免疫疗法,尤其在某些B细胞恶性肿瘤中展现出显著的抗肿瘤效果,比如:DLBCL,ALL,CLL,MM等。同时也面临一些限制:1. 不充分的细胞扩增与肿瘤浸润相关的持续反应率低;2. 在实体瘤方面缺乏客观应答;3.伴随一些致命的并发症。这些因素都和CAR-T细胞回...
前四款都是选择 CD19为治疗靶点,后两是BCMA;目前治疗领域集中在血液瘤,更多药企在逐步开展实体瘤研发;目前CAR-T均为自 体细胞疗法,通用型产品仍在研发当中。 FDA已批准六款产品上市,国内企业进展迅速 2021年NMPA先后批准复星凯特的阿基仑赛注射液和药明巨诺的瑞基奥仑赛注射液上市,两者成为国内首先获批的CAR-T ...
Metastatic HER2 + breast cancer is an expanding area of drug development and research, with three new drugs approved in 2020 alone. While first
Her2+乳腺癌:针对II-III期Her2/Neu阳性的乳腺癌患者,研究性临床,计划招募20名参与者。单臂试验,主要临床终点为治疗前后肿瘤浸润淋巴细胞(TIL)百分比的变化。 转移性结直肠癌:Ib/II期临床,59名参与者,针对共识分子亚型-4(Consensus Molecular Subtype 4)的复发难治性转移结直肠癌。
An anti-cancer virus composition including an icosahedral-shaped plant virus or virus-like particle linked to a HER2 antigen is described. The anti-cancer virus composition can be used for methods of treating or decreasing the risk of developing a HER2-expressing cancer in a subject by administeri...
protein)以顺式或融合形式表达,所述能够作为安全开关的蛋白包括诱导型caspase 9(inducible caspase 9,icasp9),cd19,cd20,egfr,her2,cd30,cd19,c-met,claudin 18.2,或其组合。 35.在另一个优选实施方案中,所述的基于anti-cd3的双特异t细胞激活元件(bita)结构如下式ii所示: ...